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Fostriecin (CI-920) is a topoisomerase (topo) II catalytic activity
inhibitor (Boritzki et al, 1988) (Figure 1). This novel class of topo
II-targeting drugs is considered of potential value for treatment of
patients with tumours resistant to classic topo II poisons, including
anthracyclines and podophyllotoxins (Cummings and Smyth,
1993). The nuclear enzyme topo II is essential for the regulation of
DNA conformation (reviewed in Osheroff et al, 1991). Central in
its action is the formation of a complex with DNA. Stabilization of
this complex by topo II poisons induces DNA damage and cell
death (Froelich-Ammon and Osheroff, 1995). Decreased complex
formation due to decreased topo II levels is considered to be an
important mechanism of tumour-resistance to topo II poisons
(Beck and Danks, 1991). The topo II catalytic inhibitor fostriecin
is expected to have increased activity against tumour cells with
low topo II levels and this was confirmed in in vitro studies (De
Jong et al, 1991). In vitro, fostriecin also inhibited nuclear protein
phosphatases involved with cell cycle regulation and histone
phosphatases involved with chromosome condensation during
mitosis (Roberge et al, 1994; Guo et al, 1995).
In preclinical studies, fostriecin was active against murine
leukaemias P388 and L1210 and one of the most active drugs in a
human tumour clonogenic assay (Leopold et al, 1984; Scheithauer
et al, 1986). Animal experiments showed increased anti-tumour
activity with prolonged exposure (Leopold et al, 1984); therefore, a
5-day schedule was chosen for this phase I study. At this schedule
the mouse LD10 was 120 mg m–2 day–1. Because of increased toxi-
city of fostriecin in dogs compared to mice, a dose below one-third
of the one-tenth mouse equivalent LD10, 2 mg m–2 day–1, was
chosen as starting dose in humans (Clinical Brochure Fostriecin,
1991). Histological studies rats showed degenerative changes in
renal cortical epithelium and necrosis of lymphoid tissue. In dogs,
increased liver transaminases were observed and histologic exami-
nations showed congestion and haemorrhage in several organs,
primarily heart and brain, at higher doses.
We also performed an analysis of the human pharmacokinetics
of fostriecin and ex vivo experiments to investigate if the plasma
drug concentrations achieved were sufficient to inhibit a tenipo-
side-resistant tumour cell line. The maximum tolerated dose
(MTD) of fostriecin could not be established because drug supply
was stopped prematurely. However, results of this study may
provide a basis for continued clinical development of this agent.
PATIENTS AND METHODS
Patient selection, drug administration and evaluation
Patient eligibility criteria were: histologically confirmed diagnosis
of a solid tumour, no longer amenable to established forms of
treatment; age 18–75 years; Eastern Cooperative Oncology Group
(ECOG) performance status ≤ 2; life expectancy ³ 12 weeks; no
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prior chemo-, immuno- or radiotherapy for at least 4 weeks before
study entry; white blood cell (WBC) count ³ 4000 ml–1 and platelet
count ³ 100 000 ml–1; bilirubin ≤ 25 mmol l–1 and aspartate–amino
transferase (AST) and alanine–amino transferase (ALT) within 2.5
times the normal upper limit; normal prothrombin time (PT);
creatinine clearance ³ 60 ml min–1. Written informed consent was
obtained from all patients. The protocol was approved by the
Medical Ethical Committee of the University Hospital Groningen.
Fostriecin was supplied by NCI (Bethesda, MD, USA) as a
lyophilized powder and was diluted with 0.9% NaCl to 50 or
100 ml. It was administered as a 60-min intravenous (IV) infusion
through an UV-light protected system on days 1–5 at 4-week
intervals. The dose was initially escalated according to the
Fibonacci scheme, with subsequent dose steps of 2, 4, 6.6, 10 and
12.2 mg m–2 day–1 and thereafter increased to 20 mg m–2 (the
protocol was amended during the study to allow more rapid dose
escalation). Three patients were entered at each dose level, with a
maximum of three additional patients when one out of three expe-
rienced dose-limiting toxicity (DLT). When no DLT was observed,
or only in one out of six patients, the subsequent group was treated
at the next higher dose level. Individual patients were treated until
progressive disease for a maximum of 6 courses.
Patients were hospitalized during drug administration. The body
temperature and blood pressure were measured four times daily,
including a measurement at the start and the end of each infusion.
Blood chemistry, including creatine kinase (CK) and urinalysis
were performed daily during treatment. During treatment-free
intervals patients were evaluated twice-weekly for toxicity. At
these evaluations full blood counts, differential, blood chemistry
including liver- and renal parameters, CK and urinalysis were
performed. In six patients (13 courses) at 10–20 mg m–2, PT,
fibrinogen, anti-thrombin III and cholinesterase were measured on
days 0 and 5 to monitor liver synthesis function.
Toxicities were graded with the NCI common toxicity criteria
(CTC). DLT was considered to be grade 4 haematologic or ³ grade
3 non-haematologic toxicity, or ³ grade 2 cardiac- or neurotoxi-
city. After the first two dose levels the protocol was modified to
consider ³ grade 3 renal- and hepatic toxicity as dose-limiting
when lasting > 7 days. The MTD was defined as the dose at which
not more than one out of three to six patients experienced DLT,
with the next higher dose level causing DLT in two or more
patients.
Pharmacokinetics
On day 1 of the first course blood samples (8 ml) were obtained
through an IV plastic catheter in the forearm contralateral to the
infusion site. The samples were collected in tubes containing
heparin sodium (Becton Dickinson Vacutainer Systems Europe,
Meylan, France) before infusion, at 30 and 45 min during infusion,
at the end of infusion, at 10, 20 and 30 min, and at 1, 1.5, 2, 4, 7
and 17 h after the end of infusion. The samples were immediately
centrifuged and the plasma was transferred into polystyrene tubes.
Urine was collected immediately before start of infusion, 0–2 h,
2–5 h and 5–18 h after start of infusion. Plasma and urine samples
were stored until analysis at –80°C.
Fostriecin plasma concentrations were determined with a high
performance liquid chromatography (HPLC) and UV-spectro-
photometric detection according to Pillon et al (1994), with modi-
fications to decrease the lower limit of quantification (LLQ).
Sulfaquinoxaline (Sigma, Zwijndrecht, The Netherlands) was used
as internal standard. Plasma samples were thawed, 0.5 ml placed in
a brown glass tube, and 100 ml 0.067 M phosphate buffer (pH 6.9)
and 100 ml sulfaquinoxaline (5 mg l–1 in ultra pure water) were
added. Then 1.5 ml acetonitrile (HPLC grade, Rathburn,
Walkerburn, UK) was added and the mixture vortexed 30 s and
centrifuged 5 min at 1500 g. The supernatant was transferred to a
second glass tube, 4 ml dichloromethane (Merck, Darmstadt,
Germany) was added and the tube vortexed and centrifuged as
above. Then 300 ml of the aqueous upper layer was transferred to a
third tube and any traces of dichloromethane were evaporated in
30 min at 40°C under vacuum. Of the residual solution, 50 ml was
injected onto a Nucleosil 100-3C18 HPLC column, 100 ´ 4.6 mm
I.D. (Bouma and Uges, 1980). The mobile phase was an acetoni-
trile plus phosphate buffer (7.5 + 92.5 v/v) solution (final pH 7.1),
at a flow rate of 1.8 ml min–1. An UV–HPLC-detector (Spectroflow
757; ABI Analytical Kratos Division, Ramsey, NJ, USA) at 268 nm
was used for detection. Concentrations were calculated on a cali-
bration curve using spiked pool human plasma which had been
handled the same way at the same time. Extraction of fostriecin was
53.7 ± 9.1% (at 287 mg l–1, n = 6). The calibration curves were
linear over the range 0.05–2 mg l–1 with a correlation coefficient (r)
³ 0.999. The LLQ was 50 mg l–1; within-run precision at 390 mg l–1
fostriecin was 4.5% (n = 6) with an accuracy of 99%.
For analysis of fostriecin in urine, 100 ml urine was mixed with
50 ml sulfaquinoxaline (5 mg l–1 in water) and 100 ml ultra pure
water. Then 750 ml phosphate buffer (0.067 M, pH 6.9) was added
and after vortexing again, 50 ml was injected onto the HPLC
column. The calibration curves were linear from 0.5 to 5 mg l–1 with
r ³ 0.999. The LLQ in urine was 0.514 mg l–1; within-run precision
at 2.57 mg l–1 fostriecin was 2.2% (n = 6) with 97.3% accuracy.
Pharmacokinetic parameters were calculated using the
MW/PHARM computer package (MediWare, Groningen, The
Netherlands) (Proost and Meijer, 1992).
In vitro analysis for anti-tumour activity of plasma
specimens
Plasma samples were assayed for in vitro cytotoxicity against the
small-cell lung cancer (SCLC) cell line GLC4/VM20x. This tenipo-
side (VM26)-resistant cell line had acquired 20-fold resistance
compared to the parental cell line GLC4, with a 50% decrease of
topo IIa, but no decrease of topo IIb, compared to GLC4. Both cell
lines had no P-glycoprotein overexpression. GLC4/VM20x was 1.7
times more sensitive to fostriecin than GLC4 (Withoff et al, 1996).
The cell lines were cultured in Roswell Park Memorial Institute
(RPMI)-1640 medium (Gibco, Paisley, UK) and 10% fetal calf
serum (Sanbio, Uden, The Netherlands), without teniposide for at
least 1 month. With a microtiterwell tetrazolium assay (Timmer-
Bosscha et al, 1989), the growth-inhibitory activity of plasma
samples collected at the time of maximal fostriecin plasma concen-
tration (Tmax) was determined. Cells (7.5 ´ 104 ml–1) were incubated
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4 days in Ham F12 medium plus Dulbecco’s modified Eagle
medium (1:1) (Life Technologies, Breda, The Netherlands) and
40% patient plasma (higher plasma concentrations caused an unac-
ceptable background signal). Growth of GLC4/VM20x exposed to
plasma collected at Tmax was compared to growth in medium
containing 40% plasma from the same patient collected before
treatment and expressed as percentage. Plasma samples from two
patients at 6.6 mg m–2 (n = 2), two at 12.2 mg m–2 (n = 2) and two at
20 mg m–2 (n = 4) were tested. Positive controls were included for
all patient samples by adding fostriecin to drug-free patient plasma.
A reference growth curve of GLC4/VM20x exposed to 0.5, 1, 2, 3, 4,
5, 7.5, 15 and 30 mM fostriecin and cultured in medium with 40%
pooled human plasma derived from 20 healthy volunteers, was
included with each separate assay. Experiments with patient
samples were performed once in quadruplicate and results
expressed as mean values ± SD. A mean reference curve was based
on results of five separate experiments, each in quadruplicate.
RESULTS
Patient characteristics are listed in Table 1. Baseline liver trans-
aminases were slightly elevated in 10 of 12 patients with liver
metastases (AST 42–52 U l–1; ALT 34–69 U l–1).
The predominant laboratory abnormalities observed during
fostriecin administration (considered at least possibly drug-
related) are listed in Table 2. Elevated liver transaminases (ALT
more than AST) were observed already at the first dose level and
were the only toxicities that reached grade 3 or 4. No concurrent
elevations of CK were observed, which excluded muscle toxicity.
There was no relationship between presence of liver metastases
and grade 3–4 liver toxicity (Fisher’s exact test: P = 0.65). ALT
elevations were highly variable and did not clearly increase with
repeated administration. ALT levels in patients with elevations
³ grade 3 during courses 1 or 2 are depicted in Figure 2. ALT
peaked between days 2 and 12 per course (median: day 2.5) and
median duration of ³ grade 3 ALT was 3.5 days (range: 1–9 days).
Grade 3 ALT persisted > 7 days, and was therefore considered
dose-limiting, in one patient at 20 mg m–2. However, no MTD
could be defined because drug supply was stopped at this dose
level. In all patients ALT and AST elevations resolved within 3
weeks after drug administration. Reversible increases of bilirubin
were observed in four patients (highest value 43 mmol l–1, conju-
gated bilirubin 18 mmol l–1). PT, fibrinogen, anti-thrombin III and
cholinesterase levels were not affected.
Elevated serum creatinine was the second most common toxi-
city. Serum creatinine peaked between days 2 and 6 (median: day
3). Transient proteinuria was observed during drug administration
at doses ³ 10 mg m–2 (grade 1 in seven patients and grade 2 in
Table 1 Patient characteristics (n = 20)
Median age in years (range) 50 (23–71)
Number
Male/female 13/7
Primary site
Colorectal cancer 10
Non-small cell lung cancer 4
Othera 6
ECOG performance score
01 3
15
22
Prior therapy
None 5
Chemotherapy alone 7
Chemotherapy and radiotherapy 8
Number of patients with metastatic diseaseb
At one site 4
At multiple sites 9
aBreast cancer, melanoma, sarcoma, medullary thyroid carcinoma, bile duct
carcinoma and adenocarcinoma of unknown primary. bIncluding liver
metastases in 12 patients.
Table 2 Predominant laboratory abnormalities during fostriecin administration (first course/all courses)
Number of CTC-grade AST CTC-grade ALT CTC-grade GGTb
Dose level patients/courses
(mg m–2) (full dose) 1 2 3 4 1 2 3 4 1 2 3 4
2 4/8 2/2a – – – 2/6 1/1 – – 0/2 1/2 – –
4 5/11 3/7 1/1 0/1 – 4/8 0/1 1/2 – 1/1 0/0 1/4 –
6.6 3/4 0/0 1/1 1/2 – 2/2 1/1 0/1 – 0/0 0/0 1/1 –
10 3/7 0/3 1/1 – – 0/0 0/3 2/2 – 2/6 0/0 1/1 –
12.2 3/8 0/0 0/3 3/4 – 0/0 0/1 2/6 1/1 1/2 1/2 1/2 –
20 2/4 0/0 0/1 1/2 – 0/0 1/2 1/2 – 1/2 0/0 1/2 –
Dose Number of CTC-grade ALPc CTC-grade bilirubind CTC-grade creatinine
level patients/courses
(mg m–2) (full dose) 1 2 3 4 2 3 4 1 2 3 4
2 4/8 1/2 – – – – – – 2/4 – – –
4 5/11 3/3 0/1 – – – – – 3/7 – – –
6.6 3/4 0/3 0/1 – – 1/1 – – 1/1 – – –
10 3/7 1/1 – – – – – – 2/3 1/4 – –
12.2 3/8 1/3 0/1 – – 2/6 0/1 – 1/5 2/3 – –
20 2/4 2/2 – – – – – – 1/1 1/2 – –
aNumber of patients developing toxicity in the first course/number of courses causing toxicity for all courses given at full dose. bGamma-glutamyl transpeptidase.
cAlkaline phosphatase. dThe CTC classification starts at grade 2 for abnormal bilirubin.Phase I study of fostriecin 885
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one). Microscopic haematuria (= grade 1) was recorded in seven
patients at doses ³ 6.6 mg m–2. All renal toxicities resolved within
1–2 weeks after the last drug dose of each course.
No leuco- or neutropenia was observed. Reversible thrombo-
cytopenia (grade 2) developed in one patient at 20 mg m–2.
Fourteen patients developed grade 1–2 anaemia.
The main symptomatic toxicities were grade 1–2 nausea/
vomiting and transient increases in body temperature. These were
observed from the first dose level and there were no obvious
dose–response relationships. Nausea/vomiting were observed in
11 patients during course 1 and during 33 of the 42 courses at full
dose. The patients responded well to metoclopramide, although
this was not given prophylactically. In 17 patients body tempera-
ture increased occasionally (in 14 during course 1), in particular
immediately or a few hours after drug administration on day 1
and/or day 2. Fever > 38°C (³ grade 2) was recorded during 11
courses in six patients and > 39°C in one. Blood cultures
performed in the latter patient were negative. No antipyretics were
given. Eight patients reported mild fatigue (grade 1–2) during drug
administration and the week thereafter.
In seven patients hyperglycaemia grade 1–2 and/or hypo-
glycaemia grade 1 was observed. One patient was known with
diabetes and insulin dose was adjusted; in the others blood glucose
normalized spontaneously. The other grade 2 toxicities included
LDH increases in three patients, and hyponatraemia and oedema
each in one patient (see below).
All toxicities, except anaemia, resolved within the 3-week treat-
ment-free interval and all subsequent courses could be adminis-
tered as scheduled. The fostriecin dose was reduced 50% in two
patients: in one patient at 4 mg m–2 after course 1 because of grade
3 liver toxicity (during the 3 subsequent courses this did not
exceed grade 2) and in one patient at 20 mg m–2 after course 2
because of grade 2 oedema with hypoalbuminaemia (28 g l–1) and
transient proteinuria (maximum: 3.3 g 24 h–1). During the subse-
quent 2 courses serum albumin was never below 31 g l–1 and only
slight peripheral oedema remained.
No tumour responses were observed in any patient (10 had
measurable disease).
Pharmacokinetics
Plasma pharmacokinetics (see Table 3) could best be described by
a two-compartment model. A close linear association of drug dose
with Cmax (Pearson’s r = 0.95, P < 0.001) and with AUC (r = 0.89,
P < 0.001) indicated linear pharmacokinetics within the investi-
gated dose range. Plasma levels decreased rapidly (Figure 3) and in
only one patient was fostriecin detectable for more then 7 h after
infusion. Pharmacokinetic parameters were calculated for the two-
compartment model: mean plasma half-life 0.36 h (t1/2a; 95% CI,
0–0.76 h) and 1.51 h (t1/2b; 95% CI, 0.41–2.61 h); mean Cl
(apparent total body clearance) 2.90 l h–1 m–2; (= 48.3 ml min–1 m–2;
95% CI, 2.24–3.57 l h–1 m–2); mean residence time (MRT)
1.19 h (95% CI,  0.41–1.97 h); mean volume of distribution (Vd)
Table 3 Fostriecin plasma pharmacokinetic parameters after a 60 min IV administration of fostriecin on day 1 of the first
course
Patient no. Dose Cmax AUC t1/2a t1/2b Cl MRT Vd
(mg m–2) (mg l–1) (mg l–1 h–1) (h) (h) (l h–1 m–2) (h) (l m–2)
1a 2 0.495 0.739 0.60 – 5.14 0.86 4.44
3a 2 0.597 0.810 0.54 – 2.40 0.77 1.86
4a 2 0.371 0.468 0.35 – 4.11 0.51 2.10
5a 4 1.163 1.360 0.50 – 2.81 0.72 2.03
6a 4 0.956 1.167 0.46 – 3.05 0.67 2.03
7 4 0.940 1.486 0.26 2.03 2.31 1.93 6.76
11 6.6 1.403 1.647 0.09 0.47 4.06 0.44 2.75
12 6.6 1.861 2.450 0.25 1.22 2.63 0.63 4.64
13 10 2.242 3.350 1.67 0.93 2.97 0.92 3.98
15 10 2.446 3.768 0.30 1.39 2.66 1.01 5.34
16 12.2 3.201 4.230 0.22 1.17 2.84 0.94 4.80
18 12.2 2.787 5.324 0.46 5.10 2.32 3.61 17.09
19b 20 3.847 4.446 0.03 0.54 4.52 0.38 3.39
20 20 6.354 9.965 0.01 0.76 1.83 0.83 2.01
Cmax = maximum plasma concentration, observed values are given; Cl = apparent total body clearance; MRT = mean residence
time; Vd = volume of distribution. aOne-compartment pharmacokinetic model because of low plasma-concentrations. In patient
nos 7–20 a two-compartment model was used (r2 ³ 0.977). bSampling performed on day 1 of course 2.
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5.64 l m–2 (95% CI, 2.16–9.11 l m–2). In one patient (no. 18) an
exceptionally large Vd was observed. Fostriecin was detectable in
urine of patient nos 12–20. Renal excretion accounted for 14.6%
(mean; 95% CI, 10–17.6%) of drug elimination in these patients.
A second compound, with a retention time approximately
25 min after fostriecin, was detected in plasma and urine of
patients who received ³ 12.2 mg m–2 fostriecin. A similar chro-
matographic peak was observed after incubation of fostriecin in
water with alkaline phosphatase (Sigma, Zwijndrecht, The
Netherlands). This indicated that the second compound was
similar to dephosphorylated fostriecin.
In vitro antitumour activity of plasma samples
The mean IC50 for fostriecin of GLC4/VM20x cultured in medium
with 40% human plasma was 5.9 mM (95% CI, 5.3–6.5 mM).
When exposed to patient samples obtained at Tmax, at most 34%
growth-inhibition of GLC4/VM20x was observed (Figure 4).
Results obtained with patient plasma incubated with fostriecin ex
vivo were compatible with the reference curves of GLC4/VM20x.
This excluded that fostriecin was inactivated by other plasma
components.
DISCUSSION
This phase I study showed that repeated daily IV fostriecin admin-
istration is possible in doses up to at least 20 mg m–2 day–1 for
5 days. At 20 mg m–2 dose-limiting liver toxicity was observed in
one patient. Drug supply was thereafter stopped by NCI, because
8% related (organic) impurities were detected in the fostriecin
batches with a new detection method. This precluded definition of
the MTD. The impurities were detected with HPLC at ± 1 mg ml–1
fostriecin. However, the clinical samples analysed in our study
contained a 150-fold lower drug concentration and no impurities
were detected in plasma and urine of our patients.
The observed toxicity pattern was quite different from that of
most conventional anti-tumour agents. Liver and renal toxicities
prevailed and there was almost no haematologic toxicity. In
contrast, in preclinical studies of fostriecin in rodents, haemato-
logic toxicity was common, alongside hepatic and renal distur-
bances (Susick et al, 1990). Similar increases of transaminases
were observed after fostriecin administration in dogs and rabbits
(Clinical Brochure Fostriecin, 1991; Pillon et al, 1994). We did not
find signs of compromised liver synthesis function. Because the
liver toxicities were asymptomatic and most often declined despite
continued administration, criteria for dose-limiting toxicity were
modified after the second dose level to allow grade 3–4 liver toxi-
cities lasting ≤ 7 days. We further analysed renal toxicity with
isotope studies to measure the glomerular filtration rate and renal
plasma flow in a subset of eight patients. These data, which
confirmed the reversibility of the renal toxicity, were published
separately (De Jong et al, 1998).
There was only a limited increase of toxicity with increasing
doses. Strikingly, elevated transaminases and serum creatinine
most often peaked before or on day 3. This implies that drug
administration for another 2–3 days did not result in a further
increase of toxicity. Because the reduced folate carrier is respon-
sible for cellular fostriecin uptake, depletion of this carrier might
explain this observation (Fry et al, 1984).
Pharmacokinetic analysis showed a rapid decrease of plasma
levels after infusion. A similar short half-life had been observed in
rabbits (Pillon et al, 1994). Only 15% of the drug was excreted with
urine. Therefore, the major part of the hydrophillic fostriecin is
expected to be metabolized, or excreted with faeces. We detected a
metabolite in plasma and urine at higher dose levels, which was
most probably dephosphorylated fostriecin. Dephosphorylation of
fostriecin is an important factor to consider, because the intact
phosphate ester bond has been shown necessary for cellular uptake
and anti-tumour activity (Fry et al, 1984; Leopold et al, 1984).
Other investigators reported a metabolite that was not dephospho-
rylated fostriecin and was also not recovered from urine (Schilsky
et al, 1994).
We investigated if plasma levels obtained in vivo could be
related to in vitro effects of fostriecin on the growth of a human
SCLC cell line, GLC4/VM20x. This cell line was selected because
of its resistance to the topo II poison teniposide due to low topo II
protein levels. Fostriecin is, in particular, expected to be of poten-
tial value in treatment of cancers with this type of drug-resistance
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against topo II poisons. Our results showed that to reach a signifi-
cant in vitro effect, i.e. > 50% growth-inhibition, higher concentra-
tions than those obtained in vivo in this study are required. These
data should be interpreted with caution because of differences in
drug behaviour in vitro and in vivo. Extrapolation to the in vivo
situation is also complicated by the fact that plasma had to be
diluted 2.5-fold for cell culture experiments. However, a compar-
ison of results obtained in vivo with the plasma samples to the
reference curve of GLC4/VM20x indicates that significant in vitro
growth-inhibition can be expected when dose is further escalated
by one or two steps of 50%.
In conclusion, further dose escalation will be necessary to
define the MTD of fostriecin. Based on in vitro investigations with
a fostriecin-sensitive SCLC model, clinical activity might be
expected at doses of 30–40 mg m–2. The toxicities encountered
over the present investigated dose range, and in particular the
limited progression with increasing doses, suggest that dose esca-
lation to this level would be feasible. For evaluation of efficacy of
fostriecin at these doses, patients with potentially sensitive
tumours should be selected. The pharmacokinetic data from the
present study indicate that the dose schedule should be reconsid-
ered, with particular attention to the feasibility of prolonged
infusion because of fostriecin’s very short half-life. Continued
research on the novel class of topo II catalytic inhibitors, of which
fostriecin is a representative, is warranted because of the limited
therapeutic options in patients with drug-resistant tumours.
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